相似文献
1
FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
AIDS Alert. 2008 May;23(5):58-9.
2
Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS. 2008 Apr;22(4):346-7.
3
FDA notifications. Ongoing safety review of abacavir, possible MI risk.
AIDS Alert. 2011 May;26(5):58-9.
4
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2.
5
FDA notifications. FDA grants approval for generic didanosine for oral solution.
AIDS Alert. 2007 Jun;22(6):68-9.
6
FDA notifications. Abacavir approved for pediatric patients.
AIDS Alert. 2009 Feb;24(2):21-2.
7
Abacavir and increased risk of myocardial infarction.
Lancet. 2008 Sep 6;372(9641):803-4; author reply 804-5. doi: 10.1016/S0140-6736(08)61331-8.
8
Anti-HIV agents. Controversial findings on abacavir and heart attacks.
TreatmentUpdate. 2008 Mar;20(2):1-5.
9
FDA notifications. Abacavir sulfate tablets tentatively approved.
AIDS Alert. 2011 May;26(5):59-60.
10
Abacavir controversy continues to brew.
Proj Inf Perspect. 2008 Sep(46):4-7.
Zotero 插件